First Time User? Enroll now.
Weather Updates: Check our weather closings and delays page to see if your facility or clinic is impacted by inclement weather.COVID-19: Vaccine information, visitor restrictions, testing, treatment, and additional resources
Home > Health Library > Hepatitis B Treatment Recommendations
The American Association for the Study of Liver Disease has made recommendations for treating long-term (chronic) hepatitis B. These recommendations are based on the presence of hepatitis B antigens in your blood, the level of hepatitis B viral DNA ( HBV DNA) in your blood, and the level of the liver enzyme alanine aminotransferase (ALT).
Chronic hepatitis B can be HBeAg-positive or -negative. This means a specific hepatitis B antigen (HBeAg) is present (positive) or is not present (negative) in your blood. High levels of HBV DNA and liver enzymes may be present in both of these types of chronic hepatitis. This points to an active viral infection and increased risk of liver damage.
Treatment with antiviral medicine is recommended if you are:footnote 1
Treatment with antiviral medicine is not recommended if you are:footnote 1
If you are either HBeAg-positive or -negative, have low levels of HBV DNA, and have cirrhosis, you may be monitored or may need a liver transplant.
The European Association for the Study of the Liver (EASL) also has guidelines for the treatment of chronic hepatitis B. According to the EASL, treatment should be considered for people with high levels of HBV DNA and/or higher-than-normal levels of the liver enzyme ALT, and moderate to severe liver inflammation. But the decision to treat should also consider a person's general health, age, and availability of antiviral medicines.footnote 2
Terrault NA, et al. (2016). AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 63(1): 261–283. DOI: 10.1002/hep.28156. Accessed May 21, 2018.
European Association for the Study of the Liver (2012). EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology, 57(1): 167–185.
Current as of:
July 1, 2021
Author: Healthwise StaffMedical Review: Kathleen Romito MD - Family MedicineAdam Husney MD - Family MedicineW. Thomas London MD - Hepatology
Current as of: July 1, 2021
Author: Healthwise Staff
Medical Review:Kathleen Romito MD - Family Medicine & Adam Husney MD - Family Medicine & W. Thomas London MD - Hepatology
To learn more about Healthwise, visit Healthwise.org.
© 1995-2021 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.